CYTEGRITY

Serial Number 98615749
730

Registration Progress

Application Filed
Jun 24, 2024
Under Examination
Apr 1, 2025
Approved for Publication
Feb 4, 2025
Published for Opposition
Feb 4, 2025
Registered

Trademark Image

CYTEGRITY

Basic Information

Serial Number
98615749
Filing Date
June 24, 2024
Published for Opposition
February 4, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Sep 24, 2025
Application
Pending
Classes
035 040 042

Rights Holder

CSL Behring Gene Therapy, Inc.

03
Address
35 N. Lake Avenue
Suite 650
Pasadena, CA 91101

Ownership History

CSL Behring Gene Therapy, Inc.

Original Applicant
03
Pasadena, CA

CSL Behring Gene Therapy, Inc.

Owner at Publication
03
Pasadena, CA

Legal Representation

Attorney
Scott D. Woldow

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

12 events
Date Code Type Description Documents
Sep 24, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 24, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 24, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 1, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 4, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 4, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 29, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 14, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 14, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 13, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 24, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 035
Electronic data collection and data submission services for business purposes in the fields of medicine and healthcare
Class 040
Custom manufacture of pharmaceuticals based on cell therapy and gene therapy; Custom manufacture of medicine, namely, personalized medicine for others based on unique characteristics and conditions of the patient
Class 042
Research and development services relating to viral vectors, cell therapies, gene therapies, and medicines; Development of pharmaceutical preparations, viral vectors, cell therapies, gene therapies, and medicines; Stem cell research services; Stem cell gene therapy services, namely, advanced inducible stable producer technology research services designed specifically for the production of lentiviral vectors; Gene therapy research; Testing, inspection, research or development of pharmaceutical preparations for gene therapy

Classification

International Classes
035 040 042